Drug Channels
Expert insights from Dr. Adam J. Fein on pharmaceutical economics and the drug distribution system. https://www.drugchannels.net/

Drug Channels's articles

  1. Media & Marketing

Managing 340B, Medicaid Drug Discounts: Technology for Collaboration – Anywhere, Anytime

Today’s guest post comes from Lindsey Alves, Vice President of Customer Success at Kalderos. Lindsey describes the challenges facing remote workers who manage government-managed drug discount programs. As she explains, all drug discount stakeholders require novel technology-enabled collaboration tools. To learn more, register for Kalderos’ panel discussion, The Dreaded Duplicate Discounts: Collaborating in the New Hybrid […]
2 min read
0
  1. Operations & Supply Chain

White Bagging Update 2022: Hospitals Battle to Boost Buy-and-Bill

The battle for control of the specialty patient continues. In 2022, specialty pharmacies—via white, brown, and clear bagging—now constitute a meaningful share of the distribution channels for provider-administered oncology drugs. However, buy-and-bill appears to have rebounded substantially at hospitals. As I explain below, this resurgence likely reflects the success of vertically-integrated hospital/specialty pharmacy/physician mega-systems against […]
2 min read
0
  1. Media & Marketing

Available for Preorder: The 2022-23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors

On October 11, 2022, Drug Channels Institute will release The 2022–23 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. This report—our thirteenth edition— remains the most comprehensive, fact-based tool for understanding and analyzing the large and growing U.S. pharmaceutical distribution industry. We are providing you with the opportunity to preorder this thoroughly updated and revised […]
2 min read
0
  1. Data & Insights

The Pulse of Electronic Benefit Verification Solutions: Know the Facts

Today’s guest post comes from Edward Hensley, Chief Commercial Officer at AssistRx. Edward compares the pros and cons of electronic benefit verification using artificial intelligence, direct connectivity, or data connectivity. He also describes the circumstances where each solution provides the greatest value. To learn more, download AssistRx’s free eBook: Specialty Drug Patient Support Programs: 2022 […]
2 min read
0
  1. Trends & External Forces

NEW: The Drug Channels 2023 Video Webinar Series

I invite you to join me for three new video webinars during 2023. These live, interactive events will be broadcast via Zoom from the Drug Channels Video studio in beautiful downtown Philadelphia. During these events, I’ll address the latest issues confronting the U.S. drug channel. Topics will be determined based on what’s happening—trends, policy changes, […]
2 min read
0
  1. Trends & External Forces

The Inflation Reduction Act: Three Unintended Consequences for Biosimilars, Health Plans, Providers, and Pharmacies

By now, you have already read innumerable articles explaining what’s in the new Inflation Reduction Act of 2022 (IRA; P.L. 117-169). Today, I want to highlight three significant—and presumably unintended—drug channel consequences from the hastily-passed IRA legislation. These include disruption to the now-booming biosimilar market, the prospects of physician/hospital vertical integration that will raise commercial […]
2 min read
0
  1. Data & Insights

Patients At Risk As Healthcare Navigates Affordability

Today’s guest post comes from Kristina Crockett, Vice President of Product Management at CoverMyMeds. Kristina discusses the affordability challenges that patients face in our complex and confusing healthcare system. She then explains how data and technology can help payers, manufacturers, and providers improve medication access. To learn more about CoverMyMeds’ comprehensive affordability solutions, download Overcoming […]
2 min read
0
  1. Trends & External Forces

Your Brand Just Got Added to a Must-Have Formulary: Now What?

Today’s guest post comes from Chris Dowd, Senior Vice President of Market Development at ConnectiveRx. Chris discusses the benefits of using in-electronic health record (EHR) messaging to communicate formulary information to both healthcare providers and patients during the patient encounter. Click here to learn more about ConnectiveRx’s in-EHR messaging You can also register for Your […]
2 min read
0
  1. Media & Marketing

Drug Channels News Roundup, August 2022: Gov. Dean vs. Maximizers, Cancer vs. Copays, Specialty Drug Trends, Biosimilar Transitivity, and Dr. G. vs. PBMs

Our news-laden summer is coming to an end. Time to pack away your bathing suit, send the kids back to school, and cherish these curated curiosities that I combed from the Drug Channels coastline: Howard Dean attacks patient-unfriendly cost shifting Cancer patients’ views of copay assistance My $0.02 on key specialty pharmacy trends Evidence for […]
2 min read
0
  1. Trends & External Forces

Informa Connect’s Copay, Reimbursement and Access Congress

Informa Connect’s Copay, Reimbursement and Access Congress Hybrid Event | October 12-14 in Philadelphia, PA www.informaconnect.com/copay Exclusive Offer: Be sure to use your exclusive promo COPAYDC to save 10% off* of your registration An important event for all aspects cost sharing, Copay, Reimbursement and Access Congress is back and better than ever! This year’s event […]
3 min read
0
  1. Shopper & Customer

The Next Great Healthcare Surge: A ‘Diagnosis Explosion’

Today’s guest post comes from H. John Beardsley, Senior Vice President of Corporate Strategy at CoverMyMeds. John discusses how a patient-centric technology solution can increase access and affordability for patients. He goes on to describe how human contact and support helps patients understand their disease and their treatment plan, thus increasing adherence. Click here to […]
2 min read
0
  1. Data & Insights

The 340B Program Climbed to $44 Billion in 2021—With Hospitals Grabbing Most of the Money

Here’s a summer surprise for fans of the 340B Drug Pricing Program: Drug Channels has just obtained the 2021 figures from the Health Resources and Services Administration (HRSA)! Even better, my Freedom of Information Act (FOIA) request was able to pry out detailed purchases by covered entity type. The data tell a familiar story. For […]
2 min read
0